Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · IEX Real-Time Price · USD
4.540
+0.040 (0.89%)
Jul 22, 2024, 10:02 AM EDT - Market open
Can-Fite BioPharma Employees
Can-Fite BioPharma had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$92,875
Profits / Employee
-$954,250
Market Cap
21.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Biora Therapeutics | 58 |
HCW Biologics | 45 |
Apollomics | 45 |
Sol-Gel Technologies | 36 |
Femasys | 34 |
CytoMed Therapeutics | 28 |
BioVie | 18 |
NeuroOne Medical Technologies | 16 |
CANF News
- 5 days ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8 - GlobeNewsWire
- 11 days ago - Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer - GlobeNewsWire
- 24 days ago - Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix - Business Wire
- 4 weeks ago - Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver - Business Wire
- 6 weeks ago - Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study - Business Wire
- 6 weeks ago - Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study - Business Wire
- 7 weeks ago - Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases - Business Wire
- 2 months ago - Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 - Business Wire